Abstract：【Objective】To explore the correlation between Arg388 monocyte nucleotide polymorphism of fibroblast growth factor receptor 4 (FGFR4) gene and pathological complete remission (pCR) in breast cancer patients treated with neoadjuvant chemotherapy.【Methods】A total of 80 patients with locally advanced breast cancer who received preoperative neoadjuvant chemotherapy in the children's Hospital Affiliated to Zhejiang University Medical College and its Second Affiliated Hospital of DNA were selected. Peripheral blood samples were collected before chemotherapy and blood was extracted. The FGFR4 gene Arg388 genotype was detected by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). The pCR status of patients after treatment was observed. The relationship between Arg388 polymorphism and PCR was analyzed.【Results】There were 15 cases of GG genotype, 25 cases of GA genotype and 40 cases of AA genotype in 80 patients. Arg388 genotype was correlated with lymph node metastasis (P<0.05). The lymph node metastasis rate of patients with GG genotype was higher than that of patients with AA genotype, and the difference was significant (P<0.05). There were 19 cases (23.75%) with postoperative pathological PCR. The PCR rate of Arg388 GG type was lower than that of AA type (P<0.05), but there was no significant difference between GA type and AA type (P>0.05). Univariate analysis showed that TNM stage, molecular typing and lymph node status were the influencing factors of PCR. Logistic analysis showed that TNM stage, molecular typing, lymph node status and Arg388 genotype were independent influencing factors of PCR (P<0.05).【Conclusion】The Arg388 genotype of FGFR4 gene is associated with pCR in patients with breast cancer. Compared with patients with type AA, the rate of lymph node metastasis in GG patients is high and pCR is low. Arg388 genotype has a certain predictive effect on pCR of breast cancer.
曹琴, 胡晓玲, 徐志江, 彭朝阳, 叶义花. FGFR4 Arg388基因型对新辅助化疗乳腺癌患者病理完全缓解的预测价值[J]. 医学临床研究, 2021, 38(9): 1392-1395.
CAO Qin, HU Xiao-ling, XU Zhi-jiang, et al. Predictive Value of FGFR4 Arg388 Genotype for Pathological Complete Remission in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1392-1395.
[1] SPRING L, GREENUP R, NIEMIERKO A, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer[J].J Natl Compr Canc Netw,2017,15(10):1216-1223.
[2] CHEN Y, SHI X E, TIAN J H, et al. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis[J].Medicine (Baltimore),2018,97(20):e10634.
[3] AHMED M A, SELZER E, DORR W, et al. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer[J].Oncotarget,2016,7(43):69976-69990.
[4] WANG S, DING Z. Fibroblast growth factor receptors in breast cancer[J].Tumour Biol,2017,39(5):1393-1394.
[5] CHA Z, ZANG Y, GUO H, et al. Retraction Note to: Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma[J].Mol Biol Rep,2016,43(7):753.
[6] ANASTASIAGI Z, LIANOS G D, IGNATIADOU E, et al. Breast cancer in young women: an overview[J].Updates Surg,2017,69(3):313-317.
[7] LOIBL S, DENKERT C, VON MINCKWITZ G. Neoadjuvant treatment of breast cancer--Clinical and research perspective[J].Breast,2015,24 Suppl 2:S73-S77.
[8] CHENT H, YANG S F, LIU Y F, et al. Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis[J].Reprod Sci,2018,25(1):86-93.
[9] CHEN L, LEI Z, MA X, et al. Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population[J].Sci Rep,2016,6(3):36-40.
[10] THUSSBAS C, NAHRIG J, STRIT S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer[J].J Clin Oncol,2006,24(23):3747-3755.
[11] MARME F, WERFT W, BENNER A, et al. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer[J].Ann Oncol,2010,21(8):1636-1642.
[12] TANG S, HAO Y, YUAN Y, et al. Role of fibroblast growth factor receptor 4 in cancer[J].Cancer Sci,2018,109(10):3024-3031.
[13] STADLER C R, KNYAZEV P, BANGE J, et al. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression[J].Cell Signal,2006,18(6):783-794.
2021, Vol. 38 
